Table 2 Applications of graphene oxide-based nanomaterials for anticancer drug and gene delivery
From: Recent progress of graphene oxide-based multifunctional nanomaterials for cancer treatment
Nanocomposites | Delivered drug/gene | Fabrication method | Highlights of the study | Ref. |
|---|---|---|---|---|
PEG–GO–SN38 | SN38 | Non-covalent interactions | ∼ 30% release in serum; IC50 values: ∼ 6 nM | Liu et al. (2008) |
PEG–GO–PTX | PTX | Non-covalent interactions | Low concentration and short time, for improving the bioavailability of PTX | Xu et al. (2014) |
FA-FGO–DOX | DOX | Non-covalent interactions | Much higher cancer cell inhibition than pure DOX under the same conditions | Liu et al. (2018) |
FA-BSA–GO–DOX | DOX | Non-covalent interactions | Drug loading efficiency at 30.43%; higher drug release at pH 5.0 | Ma et al. (2017) |
GA–GO–DOX | DOX | Non-covalent interactions | High anti-proliferative effect on tumor cells | Nascimento et al. (2016) |
CS–GO–DOX | DOX | Non-covalent interactions | Higher drug release at pH 5.3; better inhibitory effect on tumor growth | Wang et al. (2018) |
GO–MS–CPT | CPT | Adsorption | Stimuli-responsive controlled release | Tran et al. (2018) |
NGO–SS–DOX | DOX | Covalent grafting | Redox-responsive controlled release | |
GO–ssDNA | ssDNA | Non-covalent interactions | GO platform for the detection of DNA | Lu et al. (2009) |
GOCLNPs–pDNA | pDNA | Non-covalent interactions | Achieved binding to double-stranded DNA | Di Santo et al. (2019) |
GO–FACO+–siRNA–DOX | siRNA | Non-covalent interactions | Targeted delivery for drugs and genes | Cao et al. (2013) |
PEG–PEI–FA-GO–siRNA | siRNA | Non-covalent interactions | Non-viral vector delivered efficiently to tumor tissues | Du et al (2018) |
PEG–PEI–GO–pDNA–siRNA | siRNA/pDNA | Non-covalent interactions | Use photothermally enhanced intracellular trafficking of nanocarriers for light controllable gene delivery |